ES2628025T3 - Sales de piperazina como antagonistas de D3/D2 - Google Patents

Sales de piperazina como antagonistas de D3/D2 Download PDF

Info

Publication number
ES2628025T3
ES2628025T3 ES08750834.7T ES08750834T ES2628025T3 ES 2628025 T3 ES2628025 T3 ES 2628025T3 ES 08750834 T ES08750834 T ES 08750834T ES 2628025 T3 ES2628025 T3 ES 2628025T3
Authority
ES
Spain
Prior art keywords
antagonists
piperazin
dichlorophenyl
trans
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08750834.7T
Other languages
English (en)
Inventor
Éva ÁGAINÉ CSONGOR
László Czibula
Ferenc Sebök
György DOMÁNY
István GREINER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Application granted granted Critical
Publication of ES2628025T3 publication Critical patent/ES2628025T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)

Abstract

Monoclorhidrato de trans 4-{2-[4-(2,3-dichlorofenil)-piperazin-1-il]-etil}-N,N-dimetilcarbamoil-ciclohexilamina y/o hidratos y/o solvatos del mismo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
5
10
15
20
25
30
Se suspendieron 147,5 g (0,345 mol) de trans 4-{2-[4-(2,3-diclorofenil)-piperazin-1-il]-etil}-N,N-dimetilcarbamoilciclohexilamina en una mezcla de 300 ml de metanol y 1200 ml de agua destilada. La mezcla de reacción se calentó a una temperatura entre 60-75 ºC y se añadió una mezcla de 40 ml (30 %) de solución acuosa de cloruro de hidrógeno y 32 ml de agua. La mezcla de reacción se agitó a una temperatura entre 60-75 ºC. La solución homogénea obtenida de esta manera se enfrió a una temperatura entre 20-30 ºC durante 1 h después se enfrió adicionalmente a una temperatura entre 0-10 ºC y se agitó a esta temperatura durante 3 horas. El producto se aisló por filtración y se lavó con agua. De esta manera se obtuvieron 152,9 g del compuesto del título. Rendimiento: 95 %. Punto de fusión: 221-224 ºC.
La caracterización de monoclorhidrato de trans 4-{2-[4-(2,3-diclorofenil):piperazin-1-il]-etil}-N,N-dimetilcarbamoilciclohexilamina se llevó a cabo por procedimientos analíticos en fase sólida termogravimétricos (TG), colorimétricos diferenciales de barrido (DSC), espectroscópicos infrarrojos (FT-IR), espectroscópicos de Raman (FT-Raman) y de difracción en polvo de rayos X (PXRD).
En la base de las mediciones de TG y DSC la sal de monoclorhidrato de trans 4-{2-[4-(2,3-diclorofenil)-piperazin-1il]-etil}-N,N-dimetilcarbamoil-ciclohexilamina se identificó como una forma libre de disolvente y anhidra, que exhibe estabilidad térmica satisfactoria hasta aproximadamente 200 º. Después de calentar adicionalmente la sal de monoclorhidrato de trans 4-{2-[4-(2,3-diclorofenil)-piperazin-1-il]-etil}-N,N-dimetilcarbamoil-ciclohexilamina se funde por encima de 220 ºC con descomposición térmica vigorosa que acompaña simultáneamente a alta pérdida de peso, como puede verse en los termogramas (Figuras 4 y 5). La Forma I polimorfa anhidrato de monoclorhidrato de trans 4-{2-[4-(2,3-diclorofenil)-piperazin-1-il]-etil}-N,N-dimetilcarbamoil-ciclohexilamina preparada de acuerdo con la invención y su estructura cristalina pueden identificarse y caracterizarse completamente por espectros IR y Raman y patrones de difracción en polvo de rayos X (Figuras 1, 2 y 3).
Los parámetros para los procedimientos analíticos de fase sólida usados son como sigue.
Espectroscopía FT-IR
Tipo de aparato:
Thermo-Nicolet 6700
Fase (disolvente):
KBr
Resolución de espectro
4 cm-1
Número de barridos:
100
Espectroscopía FT-Raman
Tipo de aparato: Thermo-Nicolet NXR9650 Intervalo de medición: 3500 -200 cm-1 Resolución de espectro 4 cm-1 Número de barridos: 128 Funcionamiento del láser 300 mW
Difracción en polvo de rayos X
Tipo de aparato: PANanalytical X’Pert PRO Radiación: CuKα Potencial de aceleración: 40 kV Corriente del ánodo: 40 mA Goniómetro: PW3050/60 Velocidad de exposición: 0,208 º2θ/s Recipiente de la muestra: Centrifugador PW3064 Velocidad rotacional del contenedor de muestra: 1 vuelta/s Incertidumbre de la medición 2θ ± 0,2º
7
Análisis TG
Tipo de aparato: Velocidad de calentamiento: Peso de la muestra: Atmósfera:
TA Instruments TGA Q50 10 ºC/min ~5 -10 mg 60 ml/min N2
Análisis DSC
Tipo de aparato: Velocidad de calentamiento: Peso de la muestra: Tipo de recipiente: Atmósfera:
TA Instruments DSC Q10 10 ºC/min ~1 -2 mg abierto 50 ml/min N2
8

Claims (1)

  1. imagen1
ES08750834.7T 2007-05-11 2008-05-13 Sales de piperazina como antagonistas de D3/D2 Active ES2628025T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0700339A HU230748B1 (hu) 2007-05-11 2007-05-11 Új piperazin só és előállítási eljárása
HU0700339 2007-05-11
PCT/HU2008/000044 WO2008139235A2 (en) 2007-05-11 2008-05-13 Novel piperazine salts as d3/d2 antagonists

Publications (1)

Publication Number Publication Date
ES2628025T3 true ES2628025T3 (es) 2017-08-01

Family

ID=89987512

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08750834.7T Active ES2628025T3 (es) 2007-05-11 2008-05-13 Sales de piperazina como antagonistas de D3/D2

Country Status (33)

Country Link
US (1) US7943621B2 (es)
EP (1) EP2155696B1 (es)
JP (1) JP2010526861A (es)
KR (2) KR20100018493A (es)
CN (1) CN101679315B (es)
AP (1) AP2009005012A0 (es)
AU (1) AU2008249772B2 (es)
CA (1) CA2684404C (es)
CO (1) CO6241112A2 (es)
CY (1) CY1119076T1 (es)
DK (1) DK2155696T3 (es)
EA (1) EA017270B1 (es)
EC (1) ECSP099772A (es)
ES (1) ES2628025T3 (es)
GE (1) GEP20125522B (es)
HR (1) HRP20170918T1 (es)
HU (2) HU230748B1 (es)
IL (1) IL201533A0 (es)
LT (1) LT2155696T (es)
MA (1) MA31434B1 (es)
MX (1) MX2009012182A (es)
MY (1) MY148078A (es)
NI (1) NI200900203A (es)
NZ (1) NZ580642A (es)
PL (1) PL2155696T3 (es)
PT (1) PT2155696T (es)
RS (1) RS56036B1 (es)
SI (1) SI2155696T1 (es)
TN (1) TN2009000458A1 (es)
TW (1) TWI424846B (es)
UA (1) UA102225C2 (es)
WO (1) WO2008139235A2 (es)
ZA (1) ZA200907511B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148643A (en) * 2007-05-11 2013-05-15 Richter Gedeon Nyrt Solvate and crystalline forms of carbamoyl-cyclohexane derivatives
HUP0700353A2 (en) 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
HUP0700369A2 (en) 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
ES2653852T3 (es) * 2007-08-03 2018-02-09 Richter Gedeon Nyrt. Composiciones farmacéuticas que contienen ligandos del receptor de dopamina y procedimientos de tratamiento usando ligandos del receptor de dopamina
US7875610B2 (en) * 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
CA2715760C (en) * 2008-02-21 2017-06-13 Mitsubishi Tanabe Pharma Corporation Solid preparation for oral administration of cariprazine hydrochloride
AU2009270823B2 (en) 2008-07-16 2014-07-17 Richter Gedeon Nyrt. Pharmaceutical formulations containing dopamine receptor ligands
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
HU231227B1 (hu) 2012-11-29 2022-03-28 Richter Gedeon Nyrt. Transz-4-{2-[4-(2,3-diklórfenil)-piperazin-1-il]-etil}N,N-dimetilkarbamoil-ciklohexilamin skizofrénia negatív tüneteinek kezelésére
CN105218484B (zh) * 2015-09-14 2018-02-23 安徽省逸欣铭医药科技有限公司 酒石酸卡利拉嗪及其制备方法和医药用途
CN106543105B (zh) * 2015-09-22 2019-10-11 江苏恩华药业股份有限公司 一种盐酸卡利拉嗪晶型ⅳ及其制备方法
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
WO2018229794A1 (en) 2017-06-13 2018-12-20 Cipla Limited Amorphous form of cariprazine
WO2019016828A1 (en) * 2017-07-15 2019-01-24 Msn Laboratories Private Limited, R&D Center NOVEL PROCESSES FOR THE PREPARATION OF TRANS-N- {4- [2- [4- (2,3-DICHLOROPHENYL) PIPERAZIN-1-YL] ETHYL] CYCLOHEXYL} -N ', N'-DIMETHYLUMED HYDROCHLORIDE AND POLYMORPHS THIS ONE
WO2020056929A1 (zh) * 2018-09-21 2020-03-26 上海诚妙医药科技有限公司 卡利拉嗪盐酸盐的新晶型及其制备方法及其用途
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US20230355612A1 (en) 2020-08-26 2023-11-09 Shanghai Bocimed Pharmaceutical Co., Ltd. Pharmaceutically acceptable salt of cariprazine and crystal form thereof, and preparation method therefor and use thereof
JP2024537491A (ja) * 2021-10-28 2024-10-10 アッヴィ・インコーポレイテッド 大うつ病性障害の治療
CN116675654B (zh) 2022-02-22 2025-06-13 上海云晟研新生物科技有限公司 卡利拉嗪药用盐及其晶型、药物组合物、制备方法和用途
WO2024072930A1 (en) * 2022-09-30 2024-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
HUP0500170A3 (en) * 2005-02-03 2007-11-28 Richter Gedeon Nyrt Piperazine derivatives, process for producing them and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
HU0700339D0 (en) 2007-07-30
EP2155696A2 (en) 2010-02-24
UA102225C2 (ru) 2013-06-25
WO2008139235A8 (en) 2009-12-03
CN101679315A (zh) 2010-03-24
TN2009000458A1 (en) 2011-03-31
EA017270B1 (ru) 2012-11-30
PT2155696T (pt) 2017-06-02
HU230748B1 (hu) 2018-02-28
EA200971046A1 (ru) 2010-04-30
WO2008139235A2 (en) 2008-11-20
KR101668973B1 (ko) 2016-10-24
GEP20125522B (en) 2012-05-25
EP2155696B1 (en) 2017-03-22
ZA200907511B (en) 2010-07-28
NI200900203A (es) 2010-03-11
MY148078A (en) 2013-02-28
AU2008249772A1 (en) 2008-11-20
AP2009005012A0 (en) 2009-10-31
BRPI0811199A2 (pt) 2014-10-29
MX2009012182A (es) 2009-12-09
DK2155696T3 (en) 2017-07-10
ECSP099772A (es) 2009-12-28
KR20100018493A (ko) 2010-02-17
US20090023750A1 (en) 2009-01-22
AU2008249772B2 (en) 2013-09-05
TW201002323A (en) 2010-01-16
LT2155696T (lt) 2017-06-12
NZ580642A (en) 2012-02-24
CN101679315B (zh) 2013-06-12
SI2155696T1 (sl) 2017-08-31
RS56036B1 (sr) 2017-09-29
US7943621B2 (en) 2011-05-17
KR20150090264A (ko) 2015-08-05
TWI424846B (zh) 2014-02-01
CO6241112A2 (es) 2011-01-20
WO2008139235A3 (en) 2009-03-12
HUE034796T2 (en) 2018-03-28
HUP0700339A2 (en) 2009-04-28
MA31434B1 (fr) 2010-06-01
CA2684404C (en) 2013-02-05
CA2684404A1 (en) 2008-11-20
HUP0700339A3 (en) 2010-01-28
HRP20170918T1 (hr) 2017-09-22
CY1119076T1 (el) 2018-01-10
JP2010526861A (ja) 2010-08-05
HK1140473A1 (en) 2010-10-15
PL2155696T3 (pl) 2017-10-31
IL201533A0 (en) 2010-05-31

Similar Documents

Publication Publication Date Title
US8865896B2 (en) Method for preparing adenine compound
KR101668973B1 (ko) D3/d2 길항제로서 신규한 피페라진 염
CN107603269A (zh) 一类基于萘酰亚胺的荧光染料、其制备方法及应用
ES3010145T3 (en) Method of producing tetracyclic compound
KR20240144140A (ko) Kif18a 억제제의 합성
Türkmen et al. Highly soluble perylene dyes: Synthesis, photophysical and electrochemical characterizations
Appleton et al. Anti-tuberculosis natural products: synthesis and biological evaluation of pyridoacridine alkaloids related to ascididemin
US10647732B2 (en) N-annulated perylene diimide dimers with active pyrrolic N—H bonds
Shaikh et al. Electron-deficient molecules: photophysical, electrochemical, and thermal investigations of naphtho [2, 3-f] quinoxaline-7, 12-dione derivatives
CZ201589A3 (cs) Pevné formy soli Palbociclibu
Pintilie et al. Design, synthesis and docking studies of some novel fluoroquinolone compounds with antibacterial activity
ES2652151T3 (es) Método para la producción de un compuesto de piridazina
Singhal et al. Facile One-Pot Friedlander Synthesis of Functionalized Quinolines using Graphene Oxide Carbocatalyst
JP6883332B2 (ja) タグ標識可能なカルシウムイオン検出蛍光プローブ
KR20150117123A (ko) 블로난세린의 온화한 제조방법
CZ2014708A3 (cs) Soli Bedaquilinu
JPH04235976A (ja) アラルキルアミノピリミジン類の製法
Toche et al. Synthesis of novel benzo [h][1, 6] naphthyridine derivatives from 4-aminoquinoline and cyclic β-ketoester
Kowalski et al. The synthesis of cyclic and acyclic long‐chain arylpiperazine derivatives of salicylamide as serotonin receptor ligands
JP2015040176A (ja) ビス−ボロンジピロメテン系色素
WO2006013435A1 (en) Mixed solvate of olanzapine, method for preparing it and method for preparing form i of olanzapine therefrom
IT9020092A1 (it) Procedimento per la preparazione di derivati chinazolinici
Shindy et al. Cyanine dyes of new heterocyclic ring systems: Synthesis and structure-spectra studies
MacGregor et al. Ionic liquids accelerate access to N-substituted-1, 8-naphthalimides
Ueno et al. The photochemical reactions of 5H‐benzo [a] phenothiazin‐5‐one with alkylthiols and thiophenol